Clinical and virological responses to clevudine therapy of hepatocelluar carcinoma patients with chronic hepatitis B

Gut and Liver

Volumn 5, Issue 1, 2011, Pages 82-87

  Woo, Sang Myung ^a   Park, Joong Won ^a   Lee, Woo Jin ^a   Kim, Chang Min ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chronic hepatitis B virus infection; Clevudine; Hepatocellular carcinoma

Indexed keywords

CLEVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MYOPATHY; VIRUS RESISTANCE;

EID: 79952918021     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2011.5.1.82     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987;126:492-499.
3. Park KW, Park JW, Choi JI, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008;23:467-473. (Pubitemid 351342066)
4. Kim JH, Park JW, Koh DW, Lee WJ, Kim CM. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. Liver Int 2009;29:203-207.
5. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220.
6. Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007;69:813-819. (Pubitemid 47418391)
7. Kubo S, Nishiguchi S, Hamba H, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg 2001;233:139-145. (Pubitemid 32042784)
8. Yeo W, Mo FK, Chan SL, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007;45:1382-1389. (Pubitemid 46918322)
9. Lee HS, Chung YH, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2006;43:982-988. (Pubitemid 43724623)
10. Hui CK, Lau GK. Clevudine for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs 2005;14:1277-1284. (Pubitemid 41488876)
11. Korba BE, Cote PJ, Menne S, et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 2004;9:937-952. (Pubitemid 40040268)
12. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-1178.
13. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-1048.
14. Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004;10:88-98.
15. Park JW, An M, Choi JI, et al. Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2007;133:937-943.
16. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-1257. (Pubitemid 29168472)
17. Martins A, Cortez-Pinto H, Marques-Vidal P, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006;26:680-687. (Pubitemid 43994787)
18. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917. (Pubitemid 37518510)
19. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539. (Pubitemid 46374607)
20. Kim YS, Kim GH, Hwang YJ, Kwon OS, Choi DJ, Kim JH. Early development of clevudine resistance during clevudine therapy in a patient with chronic hepatitis B who received prior lamivudine therapy. Liver Int 2009;29:950-951.
21. Koh KH, Kang CJ, Kim DH, et al. Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B. Korean J Gastroenterol 2008;52:325-328.
22. Lee HJ, Eun JR, Lee CH, et al. Long-term clevudine therapy in nucleos(t)ide-naive and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases. Korean J Hepatol 2009;15:179-192.
23. Sharon A, Chu CK. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008;80:339-353.
24. Marcellin P, Mommeja-Marin H, Sacks SL, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-148. (Pubitemid 38868933)
25. Lee KS, Byun KS, Chung YH, et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology 2007;50:296-302. (Pubitemid 47091847)
26. Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080-2086.
27. Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51:829-834.